NASDAQ: ANEB
Anebulo Pharmaceuticals Inc Stock Ownership - Who owns Anebulo Pharmaceuticals?

Insider buying vs selling

Have Anebulo Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Aron R. EnglishDirector2024-12-2310,101,010$0.99
$10.00MBuy

1 of 1

ANEB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ANEB insiders and whales buy or sell their stock.

ANEB Shareholders

What type of owners hold Anebulo Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Aron R. English48.98%20,121,828$35.62MInsider
22nw LP37.65%15,467,300$27.38MInstitution
Joseph F. Lawler29.21%12,000,000$21.24MInsider
Nantahala Capital Management LLC7.39%3,036,325$5.37MInstitution
Mangrove Partners IM LLC6.15%2,525,252$4.47MInstitution
Morgan Stanley0.97%399,219$706.62kInstitution
Lvw Advisors LLC0.85%349,617$618.82kInstitution
Geode Capital Management LLC0.50%205,418$363.59kInstitution
Vanguard Group Inc0.50%204,545$362.04kInstitution
Millennium Management LLC0.39%158,967$281.37kInstitution

1 of 3

ANEB vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ANEB41.32%58.68%Net Buying
CLSD11.34%35.27%Net Buying
IRD4.48%95.52%Net Buying
VTGN36.56%63.44%Net BuyingNet Buying
FBRX45.00%55.00%Net BuyingNet Selling

Anebulo Pharmaceuticals Stock Ownership FAQ

Who owns Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ: ANEB) is owned by 55.05% institutional shareholders, 78.18% Anebulo Pharmaceuticals insiders, and 0.00% retail investors. Aron R. English is the largest individual Anebulo Pharmaceuticals shareholder, owning 20.12M shares representing 48.98% of the company. Aron R. English's Anebulo Pharmaceuticals shares are currently valued at $33.40M.

If you're new to stock investing, here's how to buy Anebulo Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.